Home » Newsletters » BioWorld Science

BioWorld Science

March 23, 2010

View Archived Issues

Pfizer presents new sodium/glucose cotransporter 2 inhibitors

Merck KGaA patents novel 11-beta-HSD1 inhibitors

Bayer's cinaciguat shows efficacy in phase IIb heart failure study

Amgen identifies new p38 MAP kinase inhibitors

Banyu discovers novel glucokinase activators

Singaporean researchers claim new Bcl-XL and Mcl-1 inhibitors for cancer

Preclinical data support neuroprotective role of PPAR agonists in PD and IR

Pegvisomant reduces IGF-I levels in patients with gigantism

Intravitreal bevacizumab is safe in patients with proliferative diabetic retinopathy

Sustained-release recombinant human growth hormone (DA-3003) evaluated in healthy subjects

EMA recommends harmonization of prescribing information for Atacand and associated names

EMA completes arbitration procedure regarding Levact and associated names

EMA recommends amendment to warning for concomitant use of clopidogrel-containing medicines and PPIs

BioDelivery Sciences provides update on development BEMA Granisetron

FDA confirms advisory committee review date for Theratechnologies' tesamorelin NDA

University of Virginia and Merck & Co. to collaborate to develop women's reproductive health drugs

Molecular Insight advances Solazed for malignant melanoma into phase I trial

Cellceutix signs agreement with Formatech for Kevetrin cancer therapy

Advaxis reports phase I survival data on ADXS11-001 in cervical cancer

Theraclone and Zenyaku Kogyo collaborate on influenza monoclonal antibody program in Japan

Vical secures funds for phase I trial of Vaxfectin-formulated H1N1 influenza vaccine

Rexahn creates Parkinson's disease scientific advisory board to support development Serdaxin

CyDex begins dosing in phase IIa CDX-353 trial in multiple myeloma

ChemoCentryx initiates phase II CCX-140 trial

Pevion Biotech's candidiasis vaccine PEV-7 enters phase I trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...